Physician profile
Arvind Das
NPI 1770527756
$6,161.24
in general payments reported to CMS, 2019-2025
32 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $347 · 2021: $520 · 2022: $404 · 2023: $1,277 · 2024: $1,361 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,077 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,077.15 |
| Education | $324.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,851.81 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $637.83 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $260.85 | 2019-2024 | |
| Harmony Biosciences LLC | $193.55 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $172.92 | 2019-2025 | Xywav |
| Covidien LP | $137.20 | 2019 | |
| Insmed, INC. | $134.17 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $105.74 | 2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.42 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Jascayd |
| Avadel Cns Pharmaceuticals, LLC | $56.56 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $47.07 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $45.99 | 2024 | |
| Mylan Specialty L.P. | $41.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.68 | 2020-2021 | |
| Amgen INC. | $34.00 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $30.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.55 | 2019-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $28.90 | 2022-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $27.41 | 2019 | |
| Gilead Sciences, INC. | $27.25 | 2021-2023 | Veklury |
| Genentech USA, INC. | $24.27 | 2019-2020 | |
| Lilly USA, LLC | $17.50 | 2025 | Zepbound |
| Greer Laboratories, INC. | $17.28 | 2019 | |
| Novo Nordisk INC | $16.93 | 2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $16.90 | 2024 | Quviviq |
| Paratek Pharmaceuticals, INC. | $16.44 | 2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $16.06 | 2022 | |
| Eisai INC. | $14.95 | 2021 | |
| Celgene Corporation | $14.84 | 2023 | Reblozyl |
| Teva Pharmaceuticals USA, INC. | $14.37 | 2019 | |
| Axsome Therapeutics, INC. | $14.01 | 2023 | Sunosi |
| Circassia INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.